
Yesterday, Novartis suffered a blow in Denmark.
During its monthly meeting, members of the Danish Medicines Council gave a thumbs-down to the Basel-based firm, which had sought support from the council to use drug Piqray (alpelisib) as a combination treatment for certain patient groups with breast cancer.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app